InnoSer, a leading preclinical contract research organization (CRO), and TissUse, a pioneer in the field of microphysiological systems (MPS) development, are pleased to announce the signing of a strategic co-marketing agreement aimed at promoting the widespread adoption of human MPS models in drug development. This unique collaboration seeks to enhance the predictive power of current preclinical drug testing efforts by integrating human-relevant MPS models into existing drug development pipelines.   

Traditional drug testing in rodent models often faces limitations due to species-specific differences in protein recognition and biological processes, which can hinder accurate prediction of human responses during the preclinical research phases. Therefore, more innovative solutions are needed to bridge the gap between preclinical and clinical research, improving translational accuracy in drug development.  

InnoSer addresses these challenges by offering integrated preclinical rodent tolerability, PK/PD and therapeutic efficacy services in both wild-type and more translational rodent models that express human or human-like features in different parts of their biology via expression of human transgenes and immune system humanization via PBMCs or CD34 HSC reconstitution. Researchers can take advantage of InnoSer’s access to human-relevant rodent models, tailored preclinical services, as well as the flexibility to adapt to various therapeutic areas, contributing to accelerated drug development.  

TissUse develops and provides proprietary HUMIMIC MPS platforms that replicate near-physiological environments, including intricate human-organ-organ interactions. These advanced platforms capture the complexities of human biology, allowing accurate prediction of human tissue responses early in the preclinical pipeline. By integrating TissUse’s HUMIMIC MPS into drug testing workflows, researchers will gain more critical insights that enhance Go/No-Go decision-making, reduce risks, and optimize development costs, boosting preclinical testing efficiency.  

Under the present co-marketing agreement, InnoSer will integrate and perform drug screening assays using TissUse’s qualified and validated MPS models alongside its drug development services. TissUse’s validated MPS models seamlessly integrate into InnoSer’s specialized preclinical research services in rodent models by providing human-relevant insights that overcome some of the current species-specific limitations in drug testing. The combined drug development platforms in turn enable more accurate prediction of drug safety, pharmacology, and therapeutic efficacy, enhancing translational relevance and improving drug development processes.  

Furthermore, this collaboration seamlessly aligns with the growing regulatory demand for complex human data in preclinical phases, highlighting the critical role these advanced systems will play in drug development. As such, offering these systems to a broader audience will open new opportunities in the biopharmaceutical industry, promoting innovative solutions and streamlining the widespread adoption of MPS models, further reinforcing their translational relevance in preclinical research.  

By offering end-to-end research solutions, InnoSer and TissUse provide essential tools to expedite drug discovery and development, increasing the efficiency and success rate of current drug development. By embracing the combined use of advanced human in vitro and in vivo models that are highly representative of human biology, InnoSer and TissUse aim to bridge a critical gap in developing new therapies.